Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko, Mitani Sangyo to Build New Plant in Toyama for APIs
June 19, 2012
- “Sales, Shares Will Follow” Tohoku ALC Opening: Mediceo President Choufuku
June 19, 2012
- DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
June 19, 2012
- Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
June 19, 2012
- Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
June 19, 2012
- [Data] Sales of Takeda’s Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Otsuka HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Astellas's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Eisai's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Dainippon Sumitomo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Taisho HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Shionogi's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Ono's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Santen's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kyorin HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kaken's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mochida's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Shinyaku's Mainstay Products in FY2011
June 19, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…